Probable causes of ECG abnormalities in Ebstein’s anomaly were investigated by comparing tracings from 18 young patients with the disease (group I) and 20 age-matched patients with a morphologically similar cardiopathy: right ventricular endomyocardial fibrosis (group II). Tall p waves (≧ 2.5 mm) occurred in about a third of the patients in each group and were attributable to right atriomegaly. 8 patients, 4 from each group, had prolonged P-R intervals (≧ 17 s) resulting from increased P-R segment (7 cases) and prolonged P-wave duration (4 cases). Right bundle branch block was, however, more prevalent in group I (44%) than in group II (5 %), and is thought to result mainly from a paucity of conduction fibres in the atrialized right ventricle in Ebstein’s anomaly and partly, in group II especially, from septal fibrosis. In both groups R-wave deflections in V3R and VI were reduced, probably because of a clockwise cardiac rotation and paucity of right ventricular muscle mass.

Keywords:
Ebstein’s anomaly, Endomyocardial fibrosis, ECG abnormalities
This content is only available via PDF.
© 1982 S. Karger AG, Basel
1982
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.